{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:14:51Z","timestamp":1790198091393,"version":"4.1.0"},"reference-count":56,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The pathophysiology of sepsis is orchestrated by a delicate and dynamic interaction between pro-inflammatory and anti-inflammatory responses. Essential factors influencing this process include interleukin-7 (IL-7), the programmed cell death protein 1\/programmed death ligand 1 (PD-1\/PD-L1) axis, and cellular apoptosis. These elements shape the immune response in sepsis, influencing its progression and outcomes. IL-7 is an important cytokine maintaining lymphocyte function and survival. At the same time, the PD-1\/PD-L1 axis acts as a modulatory checkpoint suppressing immune activation to prevent overreaction but can exacerbate immunosuppression during sepsis. Cellular apoptosis impairs the host\u2019s ability to mount an effective defence, especially against secondary infections.<\/jats:p>\n                  <jats:p>Despite extensive research, the precise mechanisms through which sepsis results in organ dysfunction and immune dysregulation remain incompletely understood. The global burden of sepsis emphasizes the urgent need for innovative approaches, paving the way for personalized, immune-based therapies.<\/jats:p>\n                  <jats:p>This review aims to delve into and synthesize the current knowledge regarding cellular apoptosis, the regulatory role of the PD-1\/PD-L1 axis, and the critical functions of IL-7 in sepsis, with a focus on their underlying mechanisms, clinical relevance, and potential as targets for future immunomodulatory treatments.<\/jats:p>","DOI":"10.2478\/jccm-2025-0003","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:55:02Z","timestamp":1747306502000},"page":"132-139","source":"Crossref","is-referenced-by-count":4,"title":["Insights into sepsis-induced apoptosis: Interplay between programmed cell death and interleukin-7"],"prefix":"10.2478","volume":"11","author":[{"given":"Anca Meda","family":"V\u0103siesiu","sequence":"first","affiliation":[{"name":"George Emil Palade University of Medicine , Pharmacy, Science, and Technology of Targu Mures , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Coman","sequence":"additional","affiliation":[{"name":"George Emil Palade University of Medicine , Pharmacy, Science, and Technology of Targu Mures , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca Stefania","family":"Fodor","sequence":"additional","affiliation":[{"name":"George Emil Palade University of Medicine , Pharmacy, Science, and Technology of Targu Mures , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Bac\u00e2rea","sequence":"additional","affiliation":[{"name":"George Emil Palade University of Medicine , Pharmacy, Science, and Technology of Targu Mures , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca-Liana","family":"Grigorescu","sequence":"additional","affiliation":[{"name":"George Emil Palade University of Medicine , Pharmacy, Science, and Technology of Targu Mures , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"2026021423021872664_j_jccm-2025-0003_ref_001","doi-asserted-by":"crossref","unstructured":"Nakamori Y, Park EJ, Shimaoka M. Immune Deregulation in Sepsis and Septic Shock: Reversing Immune Paralysis by Targeting PD-1\/PD-L1 Pathway. Front Immunol. 2021;11:624279. Published 2021 Feb 17. doi:10.3389\/fimmu.2020.624279","DOI":"10.3389\/fimmu.2020.624279"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_002","unstructured":"Global Report on the Epidemiology and Burden of Sepsis: Current Evidence, Identifying Gaps and Future Directions; Licence: CC BY-NC-SA 3.0 IGO; World Health Organization: Geneva, Switzerland, 2020; ISBN 978-92-4-001078-9"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_003","doi-asserted-by":"crossref","unstructured":"Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200\u2013211. doi:10.1016\/S0140-6736(19)32989-7","DOI":"10.1016\/S0140-6736(19)32989-7"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_004","doi-asserted-by":"crossref","unstructured":"Arefian H, Heublein S, Scherag A, et al. Hospital-related cost of sepsis: A systematic review. J Infect. 2017;74(2):107\u2013117. doi:10.1016\/j.jinf.2016.11.006","DOI":"10.1016\/j.jinf.2016.11.006"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_005","doi-asserted-by":"crossref","unstructured":"Chen Y, Guo DZ, Zhu CL, et al. The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways. Front Immunol. 2023;14:1323797. Published 2023 Dec 13. doi:10.3389\/fimmu.2023.1323797","DOI":"10.3389\/fimmu.2023.1323797"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_006","doi-asserted-by":"crossref","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181\u20131247. doi:10.1007\/s00134-021-06506-y","DOI":"10.1007\/s00134-021-06506-y"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_007","doi-asserted-by":"crossref","unstructured":"Santacroce E, D\u2019Angerio M, Ciobanu AL, et al. Advances and Challenges in Sepsis Management: Modern Tools and Future Directions. Cells. 2024;13(5):439. Published 2024 Mar 2. doi:10.3390\/cells13050439","DOI":"10.3390\/cells13050439"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_008","doi-asserted-by":"crossref","unstructured":"Huang M, Cai S, Su J. The Pathogenesis of Sepsis and Potential Therapeutic Targets. Int J Mol Sci. 2019;20(21):5376. Published 2019 Oct 29. doi:10.3390\/ijms20215376","DOI":"10.3390\/ijms20215376"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_009","doi-asserted-by":"crossref","unstructured":"Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol. 2018;14(2):121\u2013137. doi:10.1038\/nrneph.2017.165","DOI":"10.1038\/nrneph.2017.165"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_010","doi-asserted-by":"crossref","unstructured":"Janssen M, Endeman H, Bos LDJ. Targeted immunomodulation: a primer for intensivists. Intensive Care Med. 2023;49(4):462\u2013464. doi:10.1007\/s00134-023-07009-8","DOI":"10.1007\/s00134-023-07009-8"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_011","doi-asserted-by":"crossref","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801\u2013810. doi:10.1001\/jama.2016.0287","DOI":"10.1001\/jama.2016.0287"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_012","doi-asserted-by":"crossref","unstructured":"Patil NK, Bohannon JK, Sherwood ER. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression. Pharmacol Res. 2016;111:688\u2013702. doi:10.1016\/j.phrs.2016.07.019","DOI":"10.1016\/j.phrs.2016.07.019"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_013","doi-asserted-by":"crossref","unstructured":"Zhang T, Yu-Jing L, Ma T. Role of regulation of PD-1 and PD-L1 expression in sepsis. Front Immunol. 2023;14:1029438. Published 2023 Mar 9. doi:10.3389\/fimmu.2023.1029438","DOI":"10.3389\/fimmu.2023.1029438"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_014","doi-asserted-by":"crossref","unstructured":"Pool R, Gomez H, Kellum JA. Mechanisms of Organ Dysfunction in Sepsis. Crit Care Clin. 2018;34(1):63\u201380. doi:10.1016\/j.ccc.2017.08.003","DOI":"10.1016\/j.ccc.2017.08.003"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_015","doi-asserted-by":"crossref","unstructured":"Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019-results from a systematic review and meta-analysis. Crit Care. 2020;24(1):239. Published 2020 May 19. doi:10.1186\/s13054-020-02950-2","DOI":"10.1186\/s13054-020-02950-2"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_016","doi-asserted-by":"crossref","unstructured":"Relja B, Land WG. Damage-associated molecular patterns in trauma. Eur J Trauma Emerg Surg. 2020;46(4):751\u2013775. doi:10.1007\/s00068-019-01235-w","DOI":"10.1007\/s00068-019-01235-w"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_017","doi-asserted-by":"crossref","unstructured":"Sari MI, Ilyas S. The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review [published correction appears in Diagnostics (Basel). 2023 Apr 26;13(9):1555. doi: 10.3390\/diagnostics13091555]. Diagnostics (Basel). 2022;12(8):2004. Published 2022 Aug 19. doi:10.3390\/diagnostics12082004","DOI":"10.3390\/diagnostics13091555"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_018","doi-asserted-by":"crossref","unstructured":"Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: The evolution in definition, pathophysiology, and management. SAGE Open Med. 2019;7:2050312119835043. Published 2019 Mar 21. doi:10.1177\/2050312119835043","DOI":"10.1177\/2050312119835043"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_019","doi-asserted-by":"crossref","unstructured":"Fu X, Liu Z, Wang Y. Advances in the Study of Immunosuppressive Mechanisms in Sepsis. J Inflamm Res. 2023;16:3967\u20133981. Published 2023 Sep 8. doi:10.2147\/JIR.S426007","DOI":"10.2147\/JIR.S426007"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_020","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhang Y, Yuan S, Zhang J. The potential immunological mechanisms of sepsis. Front Immunol. 2024;15:1434688. Published 2024 Jul 8. doi:10.3389\/fimmu.2024.1434688","DOI":"10.3389\/fimmu.2024.1434688"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_021","doi-asserted-by":"crossref","unstructured":"Chen R, Qin S, Zhu H, et al. Dynamic monitoring of circulating CD8+ T and NK cell function in patients with septic shock. Immunol Lett. 2022;243:61\u201368. doi:10.1016\/j.imlet.2022.02.004","DOI":"10.1016\/j.imlet.2022.02.004"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_022","doi-asserted-by":"crossref","unstructured":"Wu H, Tang T, Deng H, et al. Immune checkpoint molecule Tim-3 promotes NKT cell apoptosis and predicts poorer prognosis in Sepsis. Clin Immunol. 2023;254:109249. doi:10.1016\/j.clim.2023.109249","DOI":"10.1016\/j.clim.2023.109249"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_023","doi-asserted-by":"crossref","unstructured":"Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11(12):958\u2013972. doi:10.1038\/nrd3792","DOI":"10.1038\/nrd3792"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_024","doi-asserted-by":"crossref","unstructured":"Chen J, Wang H, Guo R, Li H, Cui N. Early Expression of Functional Markers on CD4+ T Cells Predicts Outcomes in ICU Patients With Sepsis. Front Immunol. 2022;13:938538. Published 2022 Jul 11. doi:10.3389\/fimmu.2022.938538","DOI":"10.3389\/fimmu.2022.938538"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_025","doi-asserted-by":"crossref","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28. Published 2022 Jan 21. doi:10.1186\/s12943-021-01489-2","DOI":"10.1186\/s12943-021-01489-2"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_026","doi-asserted-by":"crossref","unstructured":"Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S. Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1\/PD-L1 Immune Checkpoint Blockade. Cancer Immunol Res. 2022;10(2):146\u2013153. doi:10.1158\/2326-6066.CIR-21-0515","DOI":"10.1158\/2326-6066.CIR-21-0515"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_027","doi-asserted-by":"crossref","unstructured":"Qin W, Hu L, Zhang X, et al. The Diverse Function of PD-1\/PD-L Pathway Beyond Cancer. Front Immunol. 2019;10:2298. Published 2019 Oct 4. doi:10.3389\/fimmu.2019.02298","DOI":"10.3389\/fimmu.2019.02298"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_028","doi-asserted-by":"crossref","unstructured":"Liu MY, Klement JD, Langan CJ, van Riggelen J, Liu K. Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells. Cell Immunol. 2021;366:104397. doi:10.1016\/j.cellimm.2021.104397","DOI":"10.1016\/j.cellimm.2021.104397"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_029","doi-asserted-by":"crossref","unstructured":"Dammeijer F, van Gulijk M, Mulder EE, et al. The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell. 2020;38(5):685\u2013700.e8. doi:10.1016\/j.ccell.2020.09.001","DOI":"10.1016\/j.ccell.2020.09.001"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_030","doi-asserted-by":"crossref","unstructured":"Tomino A, Tsuda M, Aoki R, et al. Increased PD-1 Expression and Altered T Cell Repertoire Diversity Predict Mortality in Patients with Septic Shock: A Preliminary Study. PLoS One. 2017;12(1):e0169653. Published 2017 Jan 10. doi:10.1371\/journal.pone.0169653","DOI":"10.1371\/journal.pone.0169653"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_031","doi-asserted-by":"crossref","unstructured":"Taylor A, Harker JA, Chanthong K, Stevenson PG, Zuniga EI, Rudd CE. Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses. Immunity. 2016;44(2):274\u2013286. doi:10.1016\/j.immuni.2016.01.018","DOI":"10.1016\/j.immuni.2016.01.018"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_032","doi-asserted-by":"crossref","unstructured":"Rossi AL, Le M, Chung CS, et al. A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction. Am J Physiol Gastrointest Liver Physiol. 2019;316(1):G106\u2013G114. doi:10.1152\/ajpgi.00204.2018","DOI":"10.1152\/ajpgi.00204.2018"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_033","doi-asserted-by":"crossref","unstructured":"Wang JF, Wang YP, Xie J, et al. Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis. Blood. 2021;138(9):806\u2013810. doi:10.1182\/blood.2020009417","DOI":"10.1182\/blood.2020009417"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_034","doi-asserted-by":"crossref","unstructured":"Holub M, D\u017eupov\u00e1 O, R\u016f\u017ekov\u00e1 M, et al. Selected Biomarkers Correlate with the Origin and Severity of Sepsis. Mediators Inflamm. 2018;2018:7028267. Published 2018 Mar 27. doi:10.1155\/2018\/7028267","DOI":"10.1155\/2018\/7028267"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_035","doi-asserted-by":"crossref","unstructured":"Jubel JM, Barbati ZR, Burger C, Wirtz DC, Schildberg FA. The Role of PD-1 in Acute and Chronic Infection. Front Immunol. 2020;11:487. Published 2020 Mar 24. doi:10.3389\/fimmu.2020.00487","DOI":"10.3389\/fimmu.2020.00487"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_036","doi-asserted-by":"crossref","unstructured":"Wilson JK, Zhao Y, Singer M, Spencer J, Shankar-Hari M. Lymphocyte subset expression and serum concentrations of PD-1\/PD-L1 in sepsis - pilot study. Crit Care. 2018;22(1):95. Published 2018 Apr 17. doi:10.1186\/s13054-018-2020-2","DOI":"10.1186\/s13054-018-2020-2"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_037","doi-asserted-by":"crossref","unstructured":"Ruan WS, Feng MX, Xu J, et al. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1\/PD-1 Axis. Front Immunol. 2020;11:1299. Published 2020 Jul 3. doi:10.3389\/fimmu.2020.01299","DOI":"10.3389\/fimmu.2020.01299"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_038","doi-asserted-by":"crossref","unstructured":"Jiang W, Li X, Wen M, et al. Increased percentage of PD-L1+ natural killer cells predicts poor prognosis in sepsis patients: a prospective observational cohort study. Crit Care. 2020;24(1):617. Published 2020 Oct 19. doi:10.1186\/s13054-020-03329-z","DOI":"10.1186\/s13054-020-03329-z"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_039","doi-asserted-by":"crossref","unstructured":"Yende S, Kellum JA, Talisa VB, et al. Long-term Host Immune Response Trajectories Among Hospitalized Patients With Sepsis. JAMA Netw Open. 2019;2(8):e198686. Published 2019 Aug 2. doi:10.1001\/jamanetworkopen.2019.8686","DOI":"10.1001\/jamanetworkopen.2019.8686"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_040","doi-asserted-by":"crossref","unstructured":"Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock. 2014;42(5):383\u2013391. doi:10.1097\/SHK.0000000000000234","DOI":"10.1097\/SHK.0000000000000234"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_041","doi-asserted-by":"crossref","unstructured":"Francois B, Jeannet R, Daix T, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3(5):e98960. Published 2018 Mar 8. doi:10.1172\/jci.insight.98960","DOI":"10.1172\/jci.insight.98960"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_042","doi-asserted-by":"crossref","unstructured":"Chang KC, Unsinger J, Davis CG, et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J. 2007;21(3):708\u2013719. doi:10.1096\/fj.06-6805com","DOI":"10.1096\/fj.06-6805com"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_043","doi-asserted-by":"crossref","unstructured":"Alpdogan O, van den Brink MR. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol. 2005;26(1):56\u201364. doi:10.1016\/j.it.2004.11.002","DOI":"10.1016\/j.it.2004.11.002"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_044","doi-asserted-by":"crossref","unstructured":"Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality?. J Clin Invest. 2016;126(1):23\u201331. doi:10.1172\/JCI82224","DOI":"10.1172\/JCI82224"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_045","doi-asserted-by":"crossref","unstructured":"Venet F, Demaret J, Blaise BJ, et al. IL-7 Restores T Lymphocyte Immunometabolic Failure in Septic Shock Patients through mTOR Activation. J Immunol. 2017;199(5):1606\u20131615. doi:10.4049\/jimmunol.1700127","DOI":"10.4049\/jimmunol.1700127"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_046","doi-asserted-by":"crossref","unstructured":"Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 2019;20(12):1584\u20131593. doi:10.1038\/s41590-019-0479-x","DOI":"10.1038\/s41590-019-0479-x"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_047","doi-asserted-by":"crossref","unstructured":"Chen D, Tang TX, Deng H, Yang XP, Tang ZH. Interleukin-7 Biology and Its Effects on Immune Cells: Mediator of Generation, Differentiation, Survival, and Homeostasis. Front Immunol. 2021;12:747324. Published 2021 Dec 2. doi:10.3389\/fimmu.2021.747324","DOI":"10.3389\/fimmu.2021.747324"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_048","doi-asserted-by":"crossref","unstructured":"Corfe SA, Paige CJ. The many roles of IL-7 in B cell development; mediator of survival, proliferation and differentiation. Semin Immunol. 2012;24(3):198\u2013208. doi:10.1016\/j.smim.2012.02.001","DOI":"10.1016\/j.smim.2012.02.001"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_049","doi-asserted-by":"crossref","unstructured":"Li R, Paul A, Ko KW, et al. Interleukin-7 induces recruitment of monocytes\/macrophages to endothelium. Eur Heart J. 2012;33(24):3114\u20133123. doi:10.1093\/eurheartj\/ehr245","DOI":"10.1093\/eurheartj\/ehr245"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_050","doi-asserted-by":"crossref","unstructured":"Basheer M, Saad E, Kananeh M, et al. Cytokine Patterns in COVID-19 Patients: Which Cytokines Predict Mortality and Which Protect Against?. Curr Issues Mol Biol. 2022;44(10):4735\u20134747. Published 2022 Oct 10. doi:10.3390\/cimb44100323","DOI":"10.3390\/cimb44100323"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_051","doi-asserted-by":"crossref","unstructured":"Venet F, Rimmel\u00e9 T, Monneret G. Management of Sepsis-Induced Immunosuppression. Crit Care Clin. 2018;34(1):97\u2013106. doi:10.1016\/j.ccc.2017.08.007","DOI":"10.1016\/j.ccc.2017.08.007"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_052","doi-asserted-by":"crossref","unstructured":"Mackall CL, Gress RE. Thymic aging and T-cell regeneration. Immunol Rev. 1997;160:91\u2013102. doi:10.1111\/j.1600-065x.1997.tb01030.x","DOI":"10.1111\/j.1600-065X.1997.tb01030.x"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_053","doi-asserted-by":"crossref","unstructured":"Yu Q, Erman B, Bhandoola A, Sharrow SO, Singer A. In vitro evidence that cytokine receptor signals are required for differentiation of double positive thymocytes into functionally mature CD8+ T cells. J Exp Med. 2003;197(4):475\u2013487. doi:10.1084\/jem.20021765","DOI":"10.1084\/jem.20021765"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_054","doi-asserted-by":"crossref","unstructured":"Sammicheli S, Ruffin N, Lantto R, Vivar N, Chiodi F, Rethi B. IL-7 modulates B cells survival and activation by inducing BAFF and CD70 expression in T cells. J Autoimmun. 2012;38(4):304\u2013314. doi:10.1016\/j.jaut.2012.01.012","DOI":"10.1016\/j.jaut.2012.01.012"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_055","doi-asserted-by":"crossref","unstructured":"Torres LK, Pickkers P, van der Poll T. Sepsis-Induced Immunosuppression. Annu Rev Physiol. 2022;84:157\u2013181. doi:10.1146\/annurev-physiol-061121-040214","DOI":"10.1146\/annurev-physiol-061121-040214"},{"key":"2026021423021872664_j_jccm-2025-0003_ref_056","doi-asserted-by":"crossref","unstructured":"Daix T, Mathonnet A, Brakenridge S, et al. Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann Intensive Care. 2023;13(1):17. Published 2023 Mar 12. doi:10.1186\/s13613-023-01109-w","DOI":"10.1186\/s13613-023-01109-w"}],"container-title":["The Journal of Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciendo.com\/pdf\/10.2478\/jccm-2025-0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T23:02:29Z","timestamp":1771110149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.2478\/jccm-2025-0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":56,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,30]]},"published-print":{"date-parts":[[2025,4,1]]}},"alternative-id":["10.2478\/jccm-2025-0003"],"URL":"https:\/\/doi.org\/10.2478\/jccm-2025-0003","relation":{},"ISSN":["2393-1817"],"issn-type":[{"value":"2393-1817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}